KZR

Kezar Life Sciences Inc

KZR, USA

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

https://www.kezarlifesciences.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KZR
stock
KZR

Kalamazoo Resources issues new unquoted options as part of employee incentive scheme MSN

Read more →
KZR
stock
KZR

ASX Stock Market News | Australian Shares smallcaps.com.au

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$6

Analyst Picks

Strong Buy

3

Buy

0

Hold

3

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.55

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-13.53 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.49 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.18

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 66.02% of the total shares of Kezar Life Sciences Inc

1.

TANG CAPITAL MANAGEMENT LLC

(9.8319%)

since

2025/06/30

2.

Suvretta Capital Management, LLC

(9.7876%)

since

2025/06/30

3.

BML Capital Management LLC

(8.6737%)

since

2025/06/30

4.

Avidity Partners Management LP

(6.8632%)

since

2025/06/30

5.

Vanguard Group Inc

(3.772%)

since

2025/06/30

6.

Orbimed Advisors, LLC

(2.6314%)

since

2025/06/30

7.

Biotech Growth Ord

(2.6314%)

since

2025/05/31

8.

Vanguard Total Stock Mkt Idx Inv

(2.5384%)

since

2025/07/31

9.

Stonepine Capital Management Llc

(2.3195%)

since

2025/06/30

10.

ADAR1 Capital Management LLC

(2.0129%)

since

2025/06/30

11.

Peapod Lane Capital LLC

(1.5721%)

since

2025/06/30

12.

Ikarian Capital, LLC

(1.4598%)

since

2025/06/30

13.

BlackRock Inc

(1.3337%)

since

2025/06/30

14.

Renaissance Technologies Corp

(1.1919%)

since

2025/06/30

15.

Qiming U.S. Ventures Management, LLC

(1.1316%)

since

2025/06/30

16.

Shay Capital LLC

(0.9239%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.8892%)

since

2025/06/30

18.

Sphera Funds Management Ltd.

(0.7994%)

since

2025/06/30

19.

Two Sigma Advisers, LLC

(0.7461%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7174%)

since

2025/07/31

21.

Bridgeway Capital Management, LLC

(0.5599%)

since

2025/06/30

22.

Bridgeway Ultra-Small Company

(0.5599%)

since

2025/06/30

23.

Fidelity Extended Market Index

(0.4594%)

since

2025/07/31

24.

Dimensional Fund Advisors, Inc.

(0.4093%)

since

2025/06/30

25.

RBF LLC

(0.3858%)

since

2025/06/30

26.

Fidelity Global Micro-Cap F

(0.3066%)

since

2025/06/30

27.

iShares Micro-Cap ETF

(0.1879%)

since

2025/08/31

28.

Fidelity Total Market Index

(0.1467%)

since

2025/07/31

29.

DFA US Targeted Value I

(0.1452%)

since

2025/07/31

30.

Extended Equity Market Fund K

(0.1406%)

since

2025/06/30

31.

NT Ext Equity Mkt Idx Fd - L

(0.1271%)

since

2025/06/30

32.

Northern Trust Extended Eq Market Idx

(0.1271%)

since

2025/06/30

33.

Dimensional US Targeted Value ETF

(0.1232%)

since

2025/08/29

34.

Fidelity Series Total Market Index

(0.1108%)

since

2025/07/31

35.

Spartan Extended Market Index Pool F

(0.1091%)

since

2025/07/31

36.

Dimensional US Small Cap ETF

(0.0698%)

since

2025/08/29

37.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0595%)

since

2024/12/31

38.

NT Ext Equity Mkt Idx Fd - NL

(0.0576%)

since

2025/06/30

39.

DFA US Micro Cap I

(0.0537%)

since

2025/07/31

40.

Vanguard Balanced Index Inv

(0.0506%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.53

EPS Estimate

-1.9567

EPS Difference

0.4267

Surprise Percent

21.8071%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.